Characterization of the cellular infiltrate during successful topical treatment of lentigo maligna with imiquimod

British Journal of Dermatology

Volumn 151, Issue 4, 2004, Pages 903-906

  Michalopoulos, P ^a   Yawalkar, Nikhil ^a   Bronnimann M ^a   Kappeler, A ^b   Braathen, L R ^a  

^a UNIVERSITY OF BERN   (Switzerland)

^b UNIVERSITY OF BERN   (Switzerland)

Author keywords

Granzyme B; Imiquimod; Langerhans cells; Lentigo maligna; T cells

Indexed keywords

ANTIGEN; CD68 ANTIGEN; CD8 ANTIGEN; GRANZYME B; IMIQUIMOD; T6 ANTIGEN; TIA 1 ANTIGEN; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CANCER RECURRENCE; CARCINOMA IN SITU; CASE REPORT; CELL INFILTRATION; DENDRITIC CELL; DERMOEPIDERMAL JUNCTION; DRUG EFFICACY; EPIDERMIS; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LYMPHOCYTE DEPLETION; MACROPHAGE; MALIGNANT LENTIGO; MELANOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; RADIATION INJURY; SKIN BIOPSY; SKIN INJURY; SOLAR RADIATION; T LYMPHOCYTE; TOPICAL DRUG ADMINISTRATION;

AMINOQUINOLINES; ANTINEOPLASTIC AGENTS; FACIAL NEOPLASMS; FEMALE; HUMANS; HUTCHINSON'S MELANOTIC FRECKLE; MIDDLE AGED; SKIN NEOPLASMS; T-LYMPHOCYTE SUBSETS;

EID: 8344258268     PISSN: 00070963     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1365-2133.2004.06176.x     Document Type: Article

References (15)

1. Caspar ZS, Dawber RP. Treatment of lentigo maligna. Australas J Dermatol 1997; 38: 1-6.
2. Schmid-Wendtner MH, Brunner B, Konz B et al. Fractionated radiotherapy of lentigo maligna and lentigo maligna melanoma in 64 patients. J Am Acad Dermatol 2000; 43: 477-82.
3. Osborne JE, Hutchinson PE. A follow-up study to investigate the efficacy of initial treatment of lentigo maligna with surgical excision. Br J Plast Surg 2002; 55: 611-15.
4. Ahmed I, Berth-Jones J. Imiquimod: a novel treatment for lentigo maligna. Br J Dermatol 2000; 143: 843-5.
5. Ormond P, Blasdale C, Leonard N et al. Treatment of lentigo maligna with imiquimod. Br J Dermatol 2002; 147: 57-65.
6. Naylor MF, Crowson N, Kuwahara R et al. Treatment of lentigo maligna with topical imiquimod. Br J Dermatol 2003; 149: 66-9.
7. Chapman MS, Spencer SK, Brennick JB. Histologic resolution of melanoma in situ (lentigo maligna) with 5% imiquimod cream. Arch Dermatol 2003; 139: 943-4.
8. Epstein E. Extensive lentigo maligna clearing with topical imiquimod. Arch Dermatol 2003; 139: 944-5.
9. Sauder DN. Imiquimod: modes of action. Br J Dermatol 2003: 149: 5-8.
10. Hurwitz DJ, Pincus L, Kupper TS. Imiquimod: a topically applied link between innate and acquired immunity. Arch Dermatol 2003; 139: 1347-50.
11. Shizuo A, Hiroaki H. Recognition of pathogen-associated molecular patterns by TLR family. Immunol Lett 2003; 85: 85-95.
12. Gibson SJ, Lindh JM, Riter TR et al. Plasmacytoid dendritic cells produce cytokines and mature in response to the TLR 7 agonists, imiquimod and resiquimod. Cell Immunol 2002; 218: 74-86.
13. Ito T, Amakawa R, Kaisho T et al. Interferon-alpha and interleukin-12 are induced differentially by Toll-like receptor 7 ligands in human blood dendritic cell subsets. J Exp Med 2002; 195: 1507-12.
14. Yawalkar N, Egli F, Hari Y et al. Infiltration of cytotoxic T cells in drug-induced cutaneous eruptions. Clin Exp Allergy 2000; 30: 847-55.
15. Suzuki H, Wang B. Shivji GM et al. Imiquimod, a topical immune response modifier, induces migration of Langerhans cells. J Invest Dermatol 2000; 114: 135-41.